Clahsen et al [20], in a study of 441 patients, reported that p53-negative cases obtained significantly more benefit from chemotherapy than p-53 positive cases, and the mechanism of resistance to doxorubicin therapy in breast cancer was related to specific p53 gene mutations. This evidence concerns the gene TP53 and breast cancer.